In a move cementing the state’s status at the forefront of the biotechnology sector, North Carolina Governor Josh Stein recently celebrated Biogen’s three-decade tenure in the Tar Heel State and the company’s hefty $2 billion investment in its future there. The governor, speaking at an event commemorating Biogen’s 30th anniversary, lauded the firm’s commitment and the broader implications for the state’s economy and healthcare landscape, revealing that “this new $2 billion investment means more innovation, more good-paying jobs, better health, and a stronger economy,” according to a statement from his office.
Deepening its roots in the local community, Biogen announced a $250,000 donation to Durham Technical Community College; the donation aims to support a new life sciences building, and by extension, energize the future talent pipeline crucial for continued growth in the biotech and pharmaceutical manufacturing spheres, the workforce in North Carolina poised to burgeon further with Biogen’s expansive footprint and the state’s life sciences industry currently backing over 225,000 jobs and driving $88.3 billion in economic activity annually.
Biogen, known for its innovative therapies targeting complex neurological afflictions such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS), employs over 1,500 residents in North Carolina, a testament to the firm’s role as a significant local employer and player in the global healthcare conversation…